Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw strong trading volume on Tuesday . 7,701 shares traded hands during trading, an increase of 143% from the previous session’s volume of 3,172 shares.The stock last traded at $21.2950 and had previously closed at $21.50.

Analyst Ratings Changes

Several research firms have recently weighed in on AAPG. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective for the company. BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Finally, Rodman & Renshaw started coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Trading Down 2.3%

The business’s 50 day moving average price is $24.01 and its 200-day moving average price is $27.03. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million for the quarter. On average, research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International during the 3rd quarter valued at about $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $204,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, XY Capital Ltd increased its stake in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the period.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.